https://www.selleckchem.com/products/U0126.html
The study provides evidence that the AHSCT can lead to significant savings in treatment costs of aggressive MS from the public payer's perspective. Although the initial cost of AHSCT is high, the costs involving AHSCT and post-AHSCT treatment could, according to our analysis, pay off in 3.9 years, when compared to the costs of disease-modifying drug therapy in aggressive MS. The study provides evidence that the AHSCT can lead to significant savings in treatment costs of aggressive MS from the public payer's perspective. To investigate the
Like
Comment
Share
